NEO Spending and interest coverage

NeoGenomics, Inc. (NEO) Spending and interest coverage

R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..

Spending and interest coverage

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

Metric	Value	Formula and calculation
R&D / revenue · 12 months	(m)	Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m).
Stock-based compensation / revenue · 12 months	(m)	Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m).
Interest coverage · 12 months	(m)	Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m).

Calculation inputs

Input	Amount with unit	Raw financial data
Research and development spending	38.17M USD	Research and Development Expense
Revenue	(m)
Stock-based compensation	36.20M USD	Share-based Payment Arrangement, Noncash Expense
Operating income	-68.44M USD	Operating Income (Loss)
Interest expense · reported / estimated	(m)	Interest Expense · Estimated expense assumptions

Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period ending	Research and development spending (USD)	Revenue (USD)	Stock-based compensation (USD)	Operating income (USD)	Interest expense · reported / estimated (USD)	R&D / revenue	SBC / revenue	Interest coverage	Interest expense basis
2026-06-30	$38.17M	(m)	$36.20M	$-68.44M	(m)	(m)	(m)	(m)	(m)
2026-03-31	$36.43M	(m)	$40.20M	$-106.30M	(m)	(m)	(m)	(m)	(m)
2025-12-31	$37.08M	(m)	$41.32M	$-115.88M	(m)	(m)	(m)	(m)	(m)
2025-09-30	$35.87M	(m)	$41.60M	$-120.87M	(m)	(m)	(m)	(m)	(m)
2025-06-30	$34.86M	(m)	$39.77M	$-115.05M	(m)	(m)	(m)	(m)	(m)
2025-03-31	$33.72M	(m)	$36.39M	$-89.36M	(m)	(m)	(m)	(m)	(m)
2024-12-31	$31.16M	(m)	$33.41M	$-92.11M	(m)	(m)	(m)	(m)	(m)
2024-09-30	$30.32M	(m)	$32.08M	$-92.28M	(m)	(m)	(m)	(m)	(m)
2024-06-30	$27.92M	(m)	$30.79M	$-95.28M	(m)	(m)	(m)	(m)	(m)
2024-03-31	$27.53M	(m)	$27.65M	$-103.23M	$6.83M	(m)	(m)	-15.10×	Reported
2023-12-31	$27.31M	(m)	$24.63M	$-107.74M	$6.91M	(m)	(m)	-15.60×	Reported
2023-09-30	$26.86M	(m)	$22.31M	$-115.55M	$-7.69M	(m)	(m)	(m)	Reported
2023-06-30	$28.88M	(m)	$19.41M	$-130.86M	$-4.71M	(m)	(m)	(m)	Reported
2023-03-31	$30.01M	(m)	$17.33M	$-140.67M	(m)	(m)	(m)	(m)	(m)
2022-12-31	$30.33M	(m)	$24.67M	$-157.62M	$1.51M	(m)	(m)	-104.66×	Reported
2022-09-30	$32.16M	(m)	$30.07M	$-172.81M	$4.07M	(m)	(m)	-42.43×	Reported
2022-06-30	$32.26M	(m)	$31.03M	$-173.01M	$5.23M	(m)	(m)	-33.08×	Reported
2022-03-31	$27.13M	(m)	$31.91M	$-155.68M	$5.21M	(m)	(m)	-29.90×	Reported
2021-12-31	$21.87M	(m)	$22.46M	$-118.75M	$5.08M	(m)	(m)	-23.37×	Reported
2021-09-30	$15.46M	(m)	$15.07M	$-71.65M	$5.57M	(m)	(m)	-12.87×	Reported
2021-06-30	$10.02M	(m)	$12.55M	$-27.27M	$6.73M	(m)	(m)	-4.05×	Reported
2021-03-31	$8.63M	(m)	$10.68M	$-23.81M	$7.38M	(m)	(m)	-3.23×	Reported
2020-12-31	$8.23M	(m)	$10.21M	$-13.99M	$7.02M	(m)	(m)	-1.99×	Reported
2020-09-30	$8.21M	(m)	$9.81M	$-17.21M	$5.21M	(m)	(m)	-3.31×	Reported
2020-06-30	$8.86M	(m)	$10.37M	$-18.22M	$2.95M	(m)	(m)	-6.18×	Reported
2020-03-31	$9.34M	(m)	$10.05M	$5.17M	$2.71M	(m)	(m)	1.91×	Reported
2019-12-31	$8.49M	(m)	$10.00M	$13.01M	$3.71M	(m)	(m)	3.50×	Reported
2019-09-30	$6.93M	(m)	$9.53M	$13.51M	(m)	(m)	(m)	(m)	(m)
2019-06-30	$4.77M	(m)	$7.45M	$13.77M	(m)	(m)	(m)	(m)	(m)
2019-03-31	$3.25M	(m)	$7.47M	$10.08M	(m)	(m)	(m)	(m)	(m)
2018-12-31	$3.00M	(m)	$6.96M	$10.04M	(m)	(m)	(m)	(m)	(m)
2018-09-30	$3.03M	(m)	$5.78M	$10.34M	(m)	(m)	(m)	(m)	(m)
2018-06-30	$3.86M	(m)	$7.35M	$4.36M	(m)	(m)	(m)	(m)	(m)
2018-03-31	$3.73M	(m)	$6.93M	$5.41M	(m)	(m)	(m)	(m)	(m)
2017-12-31	$3.64M	(m)	$6.44M	$2.32M	(m)	(m)	(m)	(m)	(m)
2017-09-30	$4.01M	(m)	$6.77M	$-5.10M	(m)	(m)	(m)	(m)	(m)
2017-06-30	$3.71M	(m)	(m)	$-340.00K	(m)	(m)	(m)	(m)	(m)
2017-03-31	$4.07M	(m)	(m)	$537.00K	(m)	(m)	(m)	(m)	(m)
2016-12-31	$4.65M	(m)	$4.98M	$2.57M	(m)	(m)	(m)	(m)	(m)
2016-09-30	$5.58M	(m)	(m)	$293.00K	(m)	(m)	(m)	(m)	(m)
2016-06-30	$5.48M	(m)	(m)	$-988.00K	(m)	(m)	(m)	(m)	(m)
2016-03-31	$4.97M	(m)	(m)	$-3.15M	(m)	(m)	(m)	(m)	(m)
2015-12-31	$4.20M	(m)	$2.89M	$-5.63M	$854.00K	(m)	(m)	-6.60×	Reported
2015-09-30	$2.76M	(m)	$1.66M	$900.00K	(m)	(m)	(m)	(m)	(m)
2015-06-30	$2.90M	(m)	$1.21M	$712.00K	(m)	(m)	(m)	(m)	(m)
2015-03-31	$2.73M	(m)	$894.00K	$1.26M	(m)	(m)	(m)	(m)	(m)
2014-12-31	$2.69M	(m)	$641.00K	$2.22M	(m)	(m)	(m)	(m)	(m)
2014-09-30	$2.92M	(m)	(m)	$2.10M	(m)	(m)	(m)	(m)	(m)
2014-06-30	$2.25M	(m)	(m)	$3.34M	(m)	(m)	(m)	(m)	(m)
2014-03-31	$2.23M	(m)	(m)	$3.26M	$969.00K	(m)	(m)	3.37×	Reported
2013-12-31	$2.44M	(m)	(m)	$3.17M	$989.00K	(m)	(m)	3.21×	Reported
2013-09-30	$2.24M	(m)	(m)	$2.17M	$1.06M	(m)	(m)	2.05×	Reported
2013-06-30	$2.71M	(m)	(m)	$321.00K	$1.12M	(m)	(m)	0.29×	Reported
2013-03-31	$2.62M	(m)	(m)	$655.00K	$1.17M	(m)	(m)	0.56×	Reported
2012-12-31	$2.28M	(m)	(m)	$1.21M	$1.15M	(m)	(m)	1.06×	Reported
2012-09-30	(m)	(m)	(m)	$1.39M	$1.06M	(m)	(m)	1.31×	Reported
2012-06-30	(m)	(m)	(m)	$2.12M	$953.00K	(m)	(m)	2.22×	Reported
2012-03-31	(m)	(m)	(m)	$1.16M	$844.00K	(m)	(m)	1.38×	Reported
2011-12-31	(m)	(m)	(m)	$-409.00K	$768.00K	(m)	(m)	-0.53×	Reported
2011-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-03-31	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2010-12-31	(m)	(m)	(m)	$-2.96M	$710.00K	(m)	(m)	-4.17×	Reported
2010-09-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2010-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
20/20 Biolabs, Inc. (AIDX)	United States	$0.005B